In 2019, the FDA approved PDL-1 inhibitor, atezolizumab, in combination with paclitaxel for the treatment of metastatic triple-negative breast cancer in people whose tumors express PD-L1 based on data from a successful clinical trial [106]. Here, CD274 is linked to triple-negative breast carcinoma.